These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32386086)

  • 21. Spatial coordination of CD8 and TCR molecules controls antigen recognition by CD8+ T-cells.
    Pecht I; Gakamsky DM
    FEBS Lett; 2005 Jun; 579(15):3336-41. PubMed ID: 15913613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
    Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
    J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality.
    Yachi PP; Ampudia J; Zal T; Gascoigne NR
    Immunity; 2006 Aug; 25(2):203-11. PubMed ID: 16872849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covalent TCR-peptide-MHC interactions induce T cell activation and redirect T cell fate in the thymus.
    Szeto C; Zareie P; Wirasinha RC; Zhang JB; Nguyen AT; Riboldi-Tunnicliffe A; La Gruta NL; Gras S; Daley SR
    Nat Commun; 2022 Aug; 13(1):4951. PubMed ID: 35999236
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Lim Y; Kim S; Kim S; Kim DI; Kang KW; Hong SH; Lee SM; Koh HR; Seo YJ
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cellular environment regulates in situ kinetics of T-cell receptor interaction with peptide major histocompatibility complex.
    Liu B; Chen W; Natarajan K; Li Z; Margulies DH; Zhu C
    Eur J Immunol; 2015 Jul; 45(7):2099-110. PubMed ID: 25944482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of Naive CD8 T Cell Response Features by Ligand Density, Affinity, and Continued Signaling via Internalized TCRs.
    Balyan R; Gund R; Ebenezer C; Khalsa JK; Verghese DA; Krishnamurthy T; George A; Bal V; Rath S; Chaudhry A
    J Immunol; 2017 Mar; 198(5):1823-1837. PubMed ID: 28100678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nagaraj S; Gupta K; Pisarev V; Kinarsky L; Sherman S; Kang L; Herber DL; Schneck J; Gabrilovich DI
    Nat Med; 2007 Jul; 13(7):828-35. PubMed ID: 17603493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantifying the strength of ligand antagonism in TCR triggering.
    Van Den Berg HA; Burroughs NJ; Rand DA
    Bull Math Biol; 2002 Jul; 64(4):781-808. PubMed ID: 12216421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate.
    Tian S; Maile R; Collins EJ; Frelinger JA
    J Immunol; 2007 Sep; 179(5):2952-60. PubMed ID: 17709510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fast on-rates allow short dwell time ligands to activate T cells.
    Govern CC; Paczosa MK; Chakraborty AK; Huseby ES
    Proc Natl Acad Sci U S A; 2010 May; 107(19):8724-9. PubMed ID: 20421471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell Receptors Engineered
    Sharma P; Harris DT; Stone JD; Kranz DM
    Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CD8-MHC class I interaction in detection and sorting efficiencies of antigen-specific T cells using MHC class I/peptide multimers: contribution of pMHC valency.
    Neveu B; Echasserieau K; Hill T; Kuus-Reichel K; Houssaint E; Bonneville M; Saulquin X
    Int Immunol; 2006 Jul; 18(7):1139-45. PubMed ID: 16751231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
    Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
    Front Immunol; 2019; 10():2076. PubMed ID: 31552033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conserved CDR3 regions in T-cell receptor (TCR) CD8(+) T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-cell leukemia virus type 1: relationship of T-cell fine specificity and major histocompatibility complex/peptide/TCR crystal structure.
    Bourcier KD; Lim DG; Ding YH; Smith KJ; Wucherpfennig K; Hafler DA
    J Virol; 2001 Oct; 75(20):9836-43. PubMed ID: 11559817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation.
    Mao CP; Peng S; Yang A; He L; Tsai YC; Hung CF; Wu TC
    Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E4032-E4040. PubMed ID: 29632186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.